Human retinal molecular weight exclusion limit and estimate of species variation.
about
Fit for the Eye: Aptamers in Ocular DisordersFcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye.Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factorTransfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheepOcular delivery of macromoleculesOptical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.Lasting controversy on ranibizumab and bevacizumab.Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.Hydrodynamic Radii of Ranibizumab, Aflibercept and Bevacizumab Measured by Time-Resolved Phosphorescence Anisotropy.Vital staining with indocyanine green: a review of the clinical and experimental studies relating to safety.Therapeutic antibodies in ophthalmology: old is new again.Ranibizumab for age-related macular degeneration.Aflibercept (VEGF Trap-Eye) for the treatment of exudative age-related macular degeneration.Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF.Current and investigational pharmacotherapeutic approaches for modulating retinal angiogenesis.Recent perspectives on the delivery of biologics to back of the eye.Development of microemulsions for ocular delivery.Mesh-supported submicron parylene-C membranes for culturing retinal pigment epithelial cells.Real world outcomes of ocriplasmin use by members of the British and Eire Association of Vitreoretinal Surgeons.Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.Examination of barriers and barrier alteration in transscleral iontophoresis.Subunits of the epithelial sodium channel family are differentially expressed in the retina of mice with ocular hypertension.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.Ocular Drug Delivery.Diffusion chamber system for testing of collagen-based cell migration barriers for separation of ligament enthesis zones in tissue-engineered ACL constructs.
P2860
Q28828283-44D1E4D5-D9B3-44D8-B6AD-F0288DD6F52FQ33519532-8591EF35-D37A-4D1D-9227-80895343B592Q33819829-59C642BD-02C0-46C5-BBAD-A98C1789EA0BQ33912465-40DBCEC7-CC07-4717-BE5A-632FC817BA7CQ34079676-AD4FD53D-300D-449C-A006-3F8B262C521EQ35016867-70F915E8-5C11-459C-9EBD-4A02A65AAE05Q35097967-A6C0988D-4567-4D16-8A14-E40AFEBFBF94Q35641933-B7E6D641-FE36-40C7-99F6-DF143C2AAF66Q36904857-70B924D4-B9C8-4788-B35C-8F7FDE757FCAQ37088862-555A4E25-0AC4-4BEF-9077-2F0B0B9B00E6Q37231739-2DB67695-D140-4A53-ADB8-6E98C9351A2FQ37848065-C63E8B7F-E08D-41DC-BA94-D9B0B5EC7A4CQ37981760-1521AEA7-8FB2-4C52-B29C-7A7F4A5308F2Q38087692-A5DDA399-4467-466E-8E3A-F445B03A74BFQ38183850-FE5988B5-E1D8-422F-937B-E7B461BDAE50Q38192060-03D0B54D-19CB-417E-ACDE-62B7DCCCFB66Q38940171-395D295A-E8A0-4E8E-9D30-9ED803D7B843Q39210541-56B7C572-A37F-494C-BA18-ADF6F0DA2F58Q39385093-C347EDD8-E14D-4B3F-B1FB-08684D432A47Q39428283-658888E8-0D90-4754-BC40-CC0227E59FD4Q41829449-62F67F40-1327-4171-95CA-B00859E5B2FBQ41891987-F0F59DA5-B6B8-450E-840C-6560D9C391C9Q46543724-8A103699-E5E2-4C73-BFC4-C4C9BADFA805Q47729137-88A274B5-A9CD-4629-849C-AF35E13A7647Q51122641-FEA6257D-3731-423F-B467-1170B85CE8B0Q51798377-6AF3CB38-D0D8-4179-831B-010A2FCB6501
P2860
Human retinal molecular weight exclusion limit and estimate of species variation.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Human retinal molecular weight exclusion limit and estimate of species variation.
@ast
Human retinal molecular weight exclusion limit and estimate of species variation.
@en
type
label
Human retinal molecular weight exclusion limit and estimate of species variation.
@ast
Human retinal molecular weight exclusion limit and estimate of species variation.
@en
prefLabel
Human retinal molecular weight exclusion limit and estimate of species variation.
@ast
Human retinal molecular weight exclusion limit and estimate of species variation.
@en
P2093
P356
P1476
Human retinal molecular weight exclusion limit and estimate of species variation.
@en
P2093
John Marshall
Jost Hillenkamp
Richard J Antcliff
P304
P356
10.1167/IOVS.02-1027
P407
P577
2003-05-01T00:00:00Z